Form 4 Filing for Jonathan Zalevsky

Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS, was granted 16,500 stock options on December 13, 2024. These options are subject to performance-based and time-based vesting requirements under the 2017 Amended and Restated Performance Incentive Plan. On July 23, 2026, the Organization and Compensation Committee determined that the performance-based vesting condition was met, and the options vested on July 24, 2026. The options have an exercise price of $15.15 and expire on December 12, 2032. Following the vesting, Zalevsky holds 16,500 shares underlying these options. The filing also notes the underlying security is Common Stock.